NCR300

Phase 1Small molecule

NNuwacell Biotechnologies Co., Ltd.

NCR300 is one of 79 small molecule programs targeting Acute Myeloid Leukemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myeloid LeukemiaActive, not recruiting

Myelodysplastic SyndromesActive, not recruiting

Acute Myeloid LeukemiaPhase 1

Active, not recruiting

Myelodysplastic SyndromesPhase 1

Active, not recruiting

Competition

Competitive Landscape

804 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Phase 3

32 2

Vanflyta

Daiichi Sankyo

Phase 3

13 3

Cerubidine

HHikma Pharmaceuticals LLC

Phase 3

31 4

Nexavar

Bayer

Phase 3

12 5

Novantrone

EMD Serono

Phase 3

19 6

Empaveli

Gilead

Phase 3

4 7

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

1 8

Zarnestra

KKura Oncology, Inc.

Phase 3

9 9

Experimental

Biogen

Phase 3

1 10

Daunorubicin or Idarubicin

Novartis

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Phase 1Not yet recruiting

Acute Myeloid Leukemia

NCT06441084

Clinical

Trials by Indication[1]

Myelodysplastic Syndromes1 trial

A Trial to Evaluate the Safety and Efficacy of NK Cells in Subjects With Myelodysplastic Syndromes

Not yet recruiting·NNuwacell Biotechnologies Co., Ltd.·Phase 1·NCT05371730·15 enrolled

Acute Myeloid Leukemia1 trial

A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation

Not yet recruiting·NNuwacell Biotechnologies Co., Ltd.·Phase 1·NCT06441084·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for NCR300. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NCR300 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NCR300. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nuwacell Biotechnologies Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: NNuwacell Biotechnologies Co., Ltd.

NCR300

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Myelodysplastic Syndromes1 trial

Acute Myeloid Leukemia1 trial

References

Drug Info

Quick Facts

Related News